Use HOPE-3 To Justify Statin Use For Primary Prevention in Non-Whites
You'll see more patients on statins for PRIMARY prevention.
We know statins improve outcomes for SECONDARY prevention. But evidence has been murkier in other patients...especially nonwhites.
Now the HOPE-3 study will provide more clarity for primary prevention patients with a 10-year CV risk of about 7.5% or higher.